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Abstract
Background: Despite identification of the major genes and pathways involved in the development
of colorectal cancer (CRC), it has become obvious that several steps in these pathways might be
bypassed by other as yet unknown genetic events that lead towards CRC. Therefore we wanted
to improve our understanding of the genetic mechanisms of CRC development.
Methods: We used microarrays to identify novel genes involved in the development of CRC. Real
time PCR was used for mRNA expression as well as to search for chromosomal abnormalities
within candidate genes. The correlation between the expression obtained by real time PCR and the
presence of the KRAS mutation was investigated.
Results: We detected significant previously undescribed underexpression in CRC for genes
SLC26A3, TPM1 and DCN, with a suggested tumour suppressor role. We also describe the
correlation between TPM1 and DCN expression and the presence of KRAS mutations in CRC.
When searching for chromosomal abnormalities, we found deletion of the TPM1 gene in one case
of CRC, but no deletions of DCN and SLC26A3 were found.
Conclusion: Our study provides further evidence of decreased mRNA expression of three
important tumour suppressor genes in cases of CRC, thus implicating them in the development of
this type of cancer. Moreover, we found underexpression of the TPM1 gene in a case of CRCs
without KRAS mutations, showing that TPM1 might serve as an alternative path of development of
CRC. This downregulation could in some cases be mediated by deletion of the TPM1 gene. On the
other hand, the correlation of DCN underexpression with the presence of KRAS mutations suggests
that DCN expression is affected by the presence of activating KRAS mutations, lowering the amount
of the important tumour suppressor protein decorin.
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Colorectal cancer (CRC) is the third most common cancer
in both men and women [1]. It remains one of the most
frequent and deadly diseases [1] despite important advan-
tages in treatment and diagnosis [2]. The evolution from
normal colonic mucosa to adenoma with different grades
of dysplasia and finally to invasive cancer is associated
with a series of genetic events occurring over a long period
[3]. Not surprisingly, the incidence of colorectal cancer
increases with age, especially after 60 years. Two pathways
have been proposed for colorectal cancer development.
The microsatellite instability (MSI) pathway is caused by
mutations in genes MLH1, MSH2, PMS2 and MSH6,
which are part of the mismatch repair system. The chro-
mosomal instability (CIN) pathway is associated with
mutations in the APC gene or loss of 5q (APC) and muta-
tions in the KRAS gene during progression of normal epi-
thelium to early adenoma [4]. Loss of 18q (SMAD2,
SMAD4, DCC) is associated with progression from early
to advanced adenoma [4]. Deletion of 17p, which con-
tains the p53 gene, is involved in progression towards can-
cer [4]. However, only a minority of CRCs possess a full
spectrum of these molecular abnormalities [5]. Moreover,
even though major genes involved in the development of
colorectal cancer have been identified, interestingly most
of them have shown only limited value in clinical use [6].
Detection of germline mutations in MLH1, MSH2, PMS2,
MSH6 and APC is used to identify individuals with a pre-
disposition for developing hereditary nonpolyposis colon
cancer (HNPCC) and familial adenomatous polyposis
(FAP), respectively. However, only a small percentage of
the population are carriers of these mutations [7,8]. On
the other hand, somatic mutations in p53, APC and KRAS
have no real prognostic value in cases of sporadic colorec-
tal cancer [6]. Nevertheless, some clinical use might come
from mutations in KRAS. They have recently been shown
to be involved in the response of CRCs to cetuximab, sug-
gesting a better response of patients without KRAS muta-
tions in CRCs [9,10]. This shows that several steps in CRC
development might be bypassed by other as yet unknown
genetic events that lead towards CRC. We therefore
wanted to improve our understanding of the genetic
mechanisms of CRC development. In turn, this might
identify new potential tumour markers useful for clinical
practice.
Methods
Samples
Sixteen samples of colorectal adenocarcinoma (CRC) and
corresponding normal tissue were collected at the Depart-
ment for Surgery at Jesenice hospital. Samples were stabi-
lized in RNAlater (Ambion, USA) solution immediately
after extraction. Samples were incubated at 4°C overnight
and stored at -20°C, according to the manufacturer's rec-
ommendations. The study was approved by the National
Medical Ethics Committee of the Republic of Slovenia. All
16 samples were evaluated by an expert pathologist at the
Institute of Pathology, Faculty of Medicine, University of
Ljubljana. Adjacent to samples stored in RNAlater tissue
sections were obtained for histological evaluation. Only
samples including within the range of 60% to 90% of
invasive tumour cells were accepted for further analysis.
Corresponding normal tissue samples contained no can-
cer cells as evaluated by pathologist. Tumour stage and
nodal status were determined for each patient (Table 1).
DNA extraction
DNA from tissue stabilized in RNAlater (Ambion, USA)
was isolated with a QIAgen kit (QIAgen) according to the
manufacturer's instructions.
Table 1: Samples, histology and presence of activating KRAS 
mutations
Number T N KRAS status
1 3 0 wt
2 1 0 wt
3 2 0 wt
4 4 2 wt
5 3 2 wt
6 3 1 12G>S
7 3 2 13G>D
8 1 0 12G>S
9 3 1 13G>D
10 4 0 13G>D
11 3 1 wt
12 3 1 wt
13 3 0 12G>S
14 3 0 12G>S
15 3 0 13G>D
16 3 0 wt
The table shows sample histological data and the presence of 
activating KRAS mutations. No activating KRAS mutations were found 
in corresponding normal tissue.
T = tumour stage, N = nodal status, KRAS status – presence or 
absence of activating KRAS mutations.Page 2 of 9
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RNA from tissue was isolated using TRI REAGENT™
(Sigma Aldrich) and the PureLinkTM Micro-to-Midi Total
RNA Purification System (Invitrogen), according to the
manufacturer's instructions. Briefly, 50 – 100 mg of tissue
was homogenized in TRI REAGENT™ using PT 3100
homogenizer (Polytron). The homogenate was centri-
fuged at 12000 × g for 10 min at 4°C to remove insoluble
material and the supernatant was transferred to a fresh
microcentrifuge tube. Samples were allowed to sit at room
temperature for 5 min, and 0.2 ml of chloroform was
added per 1 ml of TRI REAGENT™. Samples were mixed by
hand for 15 s and allowed to stand for 2 – 15 min at room
temperature. The resulting mixture was centrifuged at
12000 × g for 15 min at 4°C. The aqueous phase was
transferred to a fresh microcentrifuge tube and an equal
amount of 70% ethanol was added. Samples were trans-
ferred to a PureLinkTM Micro-to-Midi Total RNA Purifica-
tion System column (Invitrogen) and processed according
to the manufacturer's protocol. All samples were washed
from the column with 75 μl of RNAse free water.
Analysis of RNA
The quality of RNA was checked on a Bioanalyzer 2100
(Agilent) using an RNA 6000 Nano Labchip (Agilent) and
a 6000 RNA ladder as reference (Ambion). The concentra-
tion and quantity of RNA was determined with ND-1000
(Nanodrop, USA).
Preparation of aaRNA
Preparation of aaRNA was performed with an Amino Allyl
MessageAmp™ II aRNA Amplification Kit (Ambion)
according to the manufacturer's recommendations. For
each hybridization, we labelled 5 μg of normal (Cy3) and
5 μg of tumour (Cy5) mRNA. After removing the excess
dye, the RNAs were dissolved in Nexterion Hybridization
solution (Schott Nexterion).
Microarrays
Microarrays were prepared with Human Apoptosis Subset
v2.0 and Human Cancer Subset v3.0 (Operon) 70mer oli-
gonucleotides and Nexterion 70mer Oligo Microarraying
Kit (Schott Nexterion) slides. Oligonucleotides were spot-
ted using an MG1000 spotter (MicroGrid), immobilised
and stored according to the manufacturer's instructions
(Schott Nexterion). All hybridisations were performed on
HS400 (Tecan) according to the manufacturer's instruc-
tions (Schott Nexterion). We used an LS200 scanner
(Tecan) at 6 μm resolution for scanning the microarrays.
Real time PCR
We used Taqman Reverse transcription reagent (Applied
Biosystems) for cDNA synthesis. Expression of the
SLC26A3, DCN, CALM3 and TPM1 genes in tumour sam-
ples relative to their normal adjacent tissues was measured
using quantitative real time PCR based on the TaqMan®
fluorescence methodology. A ready mixture of probes and
primers specific for SLC26A3 mRNA expression (Assay-
on-Demand™, Hs00995363_m1 (Applied Biosystems)),
DCN mRNA expression (Assay-on-Demand™,
Hs00266491_m1 (Applied Biosystems)), CALM3 mRNA
expression (Assay-on-Demand™, Hs00270914_m1
(Applied Biosystems)), TPM1 mRNA expression (Assay-
on-Demand™, Hs00165966_m1 (Applied Biosystems))
and Pre-Developed TaqMan Assay Reagents Human
GAPDH (20×) mRNA (Applied Biosystems) were used as
the endogenous control gene. All measurements were
done in triplicate. The relative quantification of mRNA
levels of the target was determined using the ΔΔCT (ΔΔCT
= ΔCT normal-ΔCT tumour; ΔCT = ΔCTx-ΔCT GAPDH) method,
unless stated otherwise.
Copy number
Gene copy number was determined by using real time
PCR based on the TaqMan fluorescence methodology.
The assays, TaqMan RNase P Detection Reagents (Applied
Biosystems) and Assay-by-Design for TPM1, SLC26A3 and
DCN (Applied Biosystems) gene detection were per-
formed according to the manufacturer's instructions.
Assay-by-Design for the TPM1 gene contained the follow-
ing primers and probe: forward primer: GGAAAGTACAT-
ATCTGGGAGAAGCA, reverse primer: TTCTTGATG
GCGTCCATGGT, probe: FAM TCGCACTCCCGCTCCT.
Assay-by-Design for the SLC26A3 gene contained the fol-
lowing primers and probe: forward primer:
GCCACAGCCAACAGAAAAATCAAAAT, reverse primer:
CCTCAAAAGCATTTGTAGAATACACTGG, probe: FAM
CTGGCCACAATATAC. Assay-by-Design for the DCN
gene contained the following primers and probe: forward
primer: CTGATGACCGCGACTTCGA, reverse primer:
CGAAGATGGCATTGACAGCG, probe: FAM CCCAGTGT-
GCCCCTTC. The copy numbers of TPM1, SLC26A3 and
DCN genes were determined on the basis of the threshold
cycle difference between TPM1, SLC26A3 and DCN and
the RnaseP gene. For calculation of the copy number,
combined_gene_copy_number_assay_macro-1.xls
(Applied Biosystems) was used.
KRAS mutation detection and V64L (rs17018909) 
detection
The first exon of the KRAS gene of each tumour sample
and corresponding normal tissue was amplified with PCR
as previously described by Konig and co. [11]. Screening
for changes in PCR products was performed with Single
Stranded Conformation Analysis (SSCA) [12,13]. Sam-
ples showing different migration shifts were chosen for
sequencing. All 16 corresponding normal tissues were
also sequenced for V64L (C>A, rs17018909) polymor-
phism of the DCN gene, which might have an effect on
performance of Hs00266491_m1 Assay-on-Demand™Page 3 of 9
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BigDye Terminator Ready Reaction Mix. Sequences were
purified, dissolved and analysed on an ABI PRISM 310
Genetic Analyzer according to the manufacturer's recom-
mendations (Applied Biosystems, USA). Nucleotide
sequences were compared against the published KRAS
cDNA sequence (GenBank accession number
NM_014588) in order to define the mutation.
Data analysis
We used ArrayPro Analyser (Media Cybernetic, USA) soft-
ware for feature extraction after imaging. Acuity 4.0
(Molecular Devices, USA) was used for filtration of bad
signals, Lowess normalization and microarray data analy-
sis. We filtered out genes that were not expressed in all 16
samples and showed a median expression of 1.5 times.
Results on differentially expressed genes were compared
to 5 major expression studies available from the PubMed
GEO project [14-18] and evidence of independent valida-
tion of gene expression data was checked using the
PubMed database. All other statistical analyses were done
using SPSS 16 (SPSS inc.). We used the paired t test to
compare differences in the amount of TPM1, SLC26A3,
DCN and CALM3 mRNA between CRC and correspond-
ing normal tissue. The paired t test was also used to check
the difference in GAPDH expression between correspond-
ing normal tissue and tumour samples. The t test was also
used to compare pairs of samples with mutations in the
KRAS gene to pairs of samples without these mutations. P
< 0.05 was considered statistically significant.
Results
The expression profiles of 16 primary human colorectal
tumours were obtained by comparison of CRC mRNA
with mRNA from their corresponding normal tissue on a
3060 element microarray from Operon. In our experi-
mental design, microarrays were used as a dual colour sys-
tem in which CRC and the corresponding normal mRNA
were separately labelled, mixed and hybridised together
on each array. The acquired data were analysed with Acu-
ity 4.0 to select reliable data. Only genes present in all 16
microarrays were considered for further processing. Out of
3060 genes, 30 genes showed differential expression (see
additional file 1[14-18]).
Because of the manageable number of differentially
expressed genes, we crosschecked their expression to
already existing microarray data (see additional file 1).
Eleven out of 30 genes (SLC26A3, CASP9, VIM, LGALS4,
SRI, UGP2, LGALS3, TPM1, TUBB, MAP2K7 and CRABP2)
showed good concordance with multiple microarray
expression studies. Ten out of 30 genes (ITGB4, CALM3,
EEF1A1, HOX4A, PCDH1, KRT19, GATA2, TGFBI, RBL2,
and TNA) showed variable expression between different
studies. Interestingly, 3 genes (AD022, CORT, and
CARD10) were not included in any of these studies and 4
genes (DCN, NPC1, RAI1, TTYH1) were characterised in
only 1 study. Only CDH12 and PMP22 showed a differ-
ence between multiple expression studies and our results.
In order to enable other users comprehensively to inter-
pret and evaluate our results, original tables of complete
microarray results are available in the supplementary data
(see the GEO website at http://www.ncbi.nlm.nih.gov/
projects/geo/ Series entry: GSE14010).
Real time PCR
Relative quantification real-time PCR was used to deter-
mine the difference in expression of SCL26A3, DCN,
TPM1 and CALM3 between CRC and corresponding nor-
mal tissue (Figure 1). We used GAPDH as endogenous
control for normalization. No statistically significant dif-
ference in expression of GAPDH between corresponding
normal tissue and tumour samples was detected (paired t
test p = 0,113). These genes were chosen because they
have been shown to play a significant role in CRC devel-
opment. They also showed good concordance with other
microarray studies and no precise quantification of their
mRNA has yet been performed.
Figure 1 shows the relative average expression of genes in
comparison to normal tissue (Figure 1). In agreement
with microarrays, SLC26A3, DCN, CALM3 and TPM1
showed clear downregulation. SLC26A3 was downregu-
lated in 13 out of 16 cases (Figure 2). Two cases showed
overexpression and 1 case showed almost no change in
expression. SLC26A3 had 12.43 times lower expression in
CRC in comparison to normal tissue (p < 0.003). DCN
Significant under-expression of SLC26A3, DCN, CALM3 and TPM1 in umou  in comparis n to normal tissueFigure 1
Significant under-expression of SLC26A3, DCN, 
CALM3 and TPM1 in tumour in comparison to nor-
mal tissue. Average expression of the SLC26A3, DCN, 
CALM3 and TPM1 gene was significantly lower in CRC in 
comparison to normal tissue. Expression is shown in ΔCT 
units, whereby larger ΔCT value represents down-regulation 
of SLC26A3, DCN, CALM3 and TPM1 in comparison to smaller 
ΔCT of normal tissue.Page 4 of 9
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comparison to normal tissue, respectively (Figure 2). CRC
had on average 4.61 times less DCN than normal tissue (p
< 0.007). We also report that we did not detect V64L pol-
ymorphism in 16 corresponding normal tissues, so no
adverse effects on performance of real-time PCR was
expected, as suggested by the manufacturer. CALM3
showed underexpression in 11 and no change in 5 cases
of CRC (Figure 2). CRC had on average 1.7 times less
CALM3 than normal tissue (p < 0.003). TPM1 was under-
expressed in 9 out of 16 cases (Figure 2). In only 1 case
was TPM1 overexpressed in CRC in comparison to normal
tissue. The remaining samples showed no major differ-
ence. TPM1 was on average 1.6 times lower in CRC that
normal tissue (p < 0.015). However, when considering
only downregulated samples, 2.5 times less TPM1 mRNA
was found in CRC in comparison to normal tissue.
Copy number
So far, SLC26A3, DCN and TPM1 genes have been sug-
gested to have tumour suppressor properties. We investi-
gated the possibility that loss of alleles could be present in
the location of genes to contribute to underexpression or
inactivation of the mentioned genes. We used the real
time PCR method to evaluate the amount of allele present
in each sample. Interestingly, although we did not find
any allele loss at the site of SLC26A3 and DCN genes, we
detected 1 loss of the TPM1 allele in 16 samples of CRC
(data not shown).
Mutation detection
In order to detect mutations, we used the SSCA method
for preliminary testing and automatic sequencing for sub-
sequent confirmation of different patterns. We searched
for mutations in codon 12 and 13, since these mutations
represent 96 – 99% of all mutations detected in CRC.
Mutations in other positions, such as 66 and 146, account
for around 1–4% of all mutations, although their clinical
relevance in CRC is unclear [19]. We found activating
mutations in codon 12 and 13 in 8 out of 16 samples
(Table 1). No activating KRAS mutations were found in
corresponding normal tissue. When comparing the
expression difference between normal and tumour sam-
ples, we found significant underexpression of the DCN
gene in the group of tumours with activating KRAS muta-
tions in comparison with tumours without these muta-
tions (p < 0.05). We also found no change in expression
of the TPM1 gene in CRC cases with a mutation in KRAS,
in comparison with underexpression of the TPM1 gene in
CRCs without activating KRAS mutations (p < 0,05) (Fig-
ure 3).
Discussion
Major molecular pathways involved in the development
of colorectal cancer have been identified [4]. However,
major genes, such as p53 and APC, involved in these path-
ways have shown only limited value in clinical use [6].
Moreover, only a minority of CRCs possess a full comple-
ment of these molecular abnormalities [5]. This shows
Expression of SLC26A3, DCN, CALM3 and TPM1 in 16 CRC in comparison to normal tissueFigure 2
Expression of SLC26A3, DCN, CALM3 and TPM1 in 16 CRC in comparison to normal tissue. Expression is shown in 
ΔΔCT units, whereby a negative ΔΔCT value represents down-regulation of gene in CRC in comparison to corresponding nor-
mal tissue. Positive bar represents over-expression of gene in CRC in comparison to corresponding normal tissue.Page 5 of 9
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by other as yet unknown genetic events that lead towards
CRC. Using expression profiling, we set out to identify
genes that may play an important role in the development
of CRC, whose expression has not yet been characterized.
This is also the first study performed on a cohort of Slov-
enian patients on this scale. We were able to identify 30
differentially expressed genes (see additional file 1).
When comparing the obtained results with other studies,
only 2 genes showed a large difference in expression in
comparison to our study. It is noteworthy that 10 out of
30 genes showed variable expression between studies.
Even more interesting was the fact that we were able to
find better characterisation of expression with other meth-
ods than microarrays for only 7 of 30 genes for CRC sam-
ples (see additional file 1). These two observations show
the need to characterise expression further with other,
more precise methods, such as real time PCR.
In the group of genes showing good concordance with
other microarray studies were SLC26A3, CASP9, VIM,
LGALS4, SRI, UGP2, LGALS3, TPM1, TUBB, MAP2K7, and
CRABP2. DCN and RAI1 also showed concordance with
our results, although their expression was characterised in
only one study. When we looked for the function of these
genes, we found that three (SLC26A3, TPM1, and DCN) of
them play a tumour suppressor role. Moreover, no precise
expression analysis on clinical cases of CRC exists to con-
firm their involvement. TPM1 and DCN are also related to
the KRAS signalling pathway, suggesting that their expres-
sion might change due to the presence or absence of acti-
vating KRAS mutations in codon 12 and 13. Moreover,
the expression of none of the three genes has so far been
characterised with real time PCR in samples of CRC.
The SLC26A3 gene encodes anion transporter expressed in
mucosa of the lower gastrointestinal tract [20]. Mutations
in the SLC26A3 gene cause congenital chloride diarrhea
(CLD) [21]. This rare condition is attributed to a lack of
chlorine uptake in the colon [22]. Patients with CLD also
have a higher risk of developing CRC [23]. Chapman et al
also demonstrated that SLC26A3 possesses a tumour sup-
pressor ability by inhibiting cell growth in cells trans-
fected with functional SLC26A3. Moreover, they showed
that the tumour suppressor role is separated from the role
of anion transporter [24]. This suggests that SLC26A3 is
not downregulated as a result of transition of normal
colon mucosa towards CRC, but plays an active role in
CRC development. The few studies investigating expres-
sion of SLC26A3 so far have only used subtractive hybrid-
ization and northern blot to show that SLC26A3 is
downregulated in adenomas of colon. Using northern
blot analysis, Anthalis et al. observed progressive down-
regulation of SLC26A3 from normal mucosa to polyp and
finally to CRC [25]. These methods are not as precise as
the real time PCR method used in this study, which pro-
vides more accurate and reproducible quantification with
a larger dynamic range. In agreement with above men-
tioned data, we report underexpression of SLC26A3 in
CRC in comparison with corresponding normal tissue.
SLC26A3 mRNA was on average 12.4 times underex-
pressed (p < 0.01) in CRC than normal surrounding
mucosa. Because abnormalities of chromosome 7 have
been associated with colorectal carcinoma, we also
hypothesised that loss of alleles might lead to underex-
pression of SLC26A3. However, no loss of SLC26A3 was
detected using the real-time PCR methodology, showing
that some other mechanism must be involved in down-
regulation of the SLC26A3 gene.
Decorin is a member of the small leucine-rich proteogly-
can gene family. Implication of decorin in the regulation
of cell cycle has been suggested by numerous studies.
Overexpression of decorin in Chinese hamster ovary cells
inhibits cell proliferation [26]. Santra et al. showed that de
novo expression of decorin leads to an arrest of trans-
formed cells in the G1 phase of the cell cycle. Moreover,
they were able to restore growth by blocking decorin tran-
scription via aDcns [27]. The tumour suppressor activity
of decorin is mediated through various pathways. Seidler
and co. showed that decorin causes a reduction of activity
and decline in total EGFR in tumour cells. Moreover, the
same group showed that decorin also activates caspase-3,
the key enzyme in apoptosis [28]. Decorin causes the
induction of p21, which in turn leads to growth suppres-
sion [29]. Decorin also has binding sites for TGF-β,
Expression of DCN and TPM1 in pairs of samples with a dif-ferent KRAS statusFigure 3
Expression of DCN and TPM1 in pairs of samples with 
a different KRAS status. Expression is shown in ΔΔCT 
units, whereby a negative ΔΔCT value represents down-regu-
lation of DCN, TPM1 in comparison to normal tissue. Pairs of 
samples were grouped according to their KRAS status.Page 6 of 9
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important citokine [30]. Interestingly, although many
tumour suppressor effects have been associated with deco-
rin, no precise quantification by real time PCR has been
performed. However, decorin protein under-expression in
CRC has been clearly established using immunohisto-
chemistry [31]. We are the first to report and characterise
decorin expression on the mRNA level using a real-time
PCR quantification method. Our results show that the
DCN gene is 4.6 times (p < 0.01) underexpressed in
tumour than normal tissue. However, in two CRC sam-
ples we found decorin overexpression in comparison to
normal tissue. Because Decorin acts through EGFR, we
speculated that we might see a difference in DCN expres-
sion between CRCs with KRAS mutations and CRCs with-
out them. We found that CRCs with activating mutations
in the KRAS gene showed much larger underexpression of
the DCN gene in comparison to normal tissue than CRCs
without mutations in KRAS. In the Fearon and Vogelstein
model, activating KRAS mutations are one of the first
genomic events leading to the development of CRC. This
in turn suggests that underexpression of the DCN gene
might be early consequence of acquired activating KRAS
mutations [32]. Moreover, as reported previously, overex-
pression of decorin also plays a role in TGF-β by inhibit-
ing its synthesis and bioactivity, thus entering another
important CRC development pathway as a tumour sup-
pressor gene [30]. The importance of decorin downregu-
lation for the development of CRC is further emphasized
by its downregulation despite the absence of activating
KRAS mutations. Lastly, we found no deletions of the
DCN gene using the real-time PCR method, showing that
either methylation of promoter or suppression by trans-
activating elements must be responsible for DCN under-
expression in a tumour.
Tropomyosines are important actin binding proteins. The
actin cytoskeleton plays an important role in regulation of
cell proliferation, apoptosis, cell migration, invasion and
anchorage independent growth [33]. Tropomysine 1 is
consistently abolished in a number of human cancer cell
lines and tissues [34,35]. Moreover, it has been demon-
strated that tropomysin 1 (TPM1) has tumour suppressor
properties [36] and it can revert transformed phenotype
[37]. Despite the obvious importance of TPM1 in tumour
development, data on TPM1 gene expression in clinical
samples of CRC samples in comparison to corresponding
normal tissue do not exist. Our data obtained by real-time
PCR show 1.6 times lower expression of TPM1 in CRCs,
which supports the current view of TPM1 as a tumour sup-
pressor. TPM1 was underexpressed in 9 out of 16 cases, in
6 samples no major difference between CRC and normal
tissue was found and in 1 case we found TPM1 overexpres-
sion. More interesting was the observation that TPM1 was
much more underexpressed in CRCs not harbouring
KRAS mutations in comparison to normal tissue. In CRCs
with a KRAS mutation, we found almost no difference in
expression to normal tissue. This observation suggests the
conclusion that downregulation of TPM1 is independent
of the constitutively activated KRAS pathway. This is also
in agreement with the observation that epigenetic factors
such as methylation of the promoter region cause TPM1
downregulation. Moreover, we also report identification
of TPM1 gene loss in 1 CRC, showing that loss of genetic
material could also be responsible for underexpression of
the TPM1 gene. This is in agreement with the hypothesis
that epigenetic and genetic events are responsible for
TPM1 downregulation, rather than inhibition by trans
acting elements.
One of the interesting results from microarrays was under-
expression of the CALM3 gene, which codes for calmodu-
lin protein. Since expression of calmodulin 3 was variable
among different microarray studies (see additional file 1)
we validated our result with real-time PCR and confirmed
the observed underexpression of CALM3 in CRC. How-
ever, this result is in contrast with its proposed cell cycle
promotion role, which is reflected by the arrest of the
mitotic cycle by anti-CaM drugs added to a wide variety of
cells [38]. Moreover, addition of monoclonal antibody
against CaM inhibited DNA synthesis and progression
through G1, and mitosis exit was sensitive to intracellular
concentrations of CaM [39]. Calmodulin in higher verte-
brates is encoded by three genes, although all three genes
code for an identical calmodulin protein consisting of 148
amino acids [40]. This raises the question of whether the
other two CALM genes are expressed in a different way.
Surprisingly, both CALM1 and CALM2 showed significant
underexpression, as reported by various microarray stud-
ies [14-17]. This observation supports the hypothesis pro-
posed by Kahl and Means that cancer cells containing a
disruption in the cyclin D/cdk4 7 pRb regulatory pathway,
may no longer require Ca2+/CaM to regulate the activa-
tion of this pathway because it is already activated or
unnecessary for G1 progression in the tumour cells [38].
One other possible explanation of such a result is that the
position in the cell rather than the amount of calmodulin
is enough to promote cell cycle. The cell could achieve this
positioning of calmodulin by targeting CALM mRNAs to
a different intracellular compartment [41,42].
Conclusion
In conclusion, we detected significant under-expression of
genes SLC26A3, TPM1, DCN and CALM3 in CRC, provid-
ing further evidence of their decreased mRNA expression
and thus implicating them in the development of this type
of cancer. We also described a correlation between TPM1
and DCN expression and the presence of KRAS mutations
in CRC. When searching for chromosomal abnormalities,
we found deletion of the TPM1 gene in one case of CRC,Page 7 of 9
(page number not for citation purposes)
BMC Cancer 2009, 9:282 http://www.biomedcentral.com/1471-2407/9/282and no deletions of DCN and SLC26A3 were found. More-
over, we found underexpression of the TPM1 gene in cases
of CRCs without KRAS mutations, showing that TPM1
might serve as an alternative path of development of CRC.
This downregulation could in some cases be mediated by
deletion of the TPM1 gene. On the other hand, the corre-
lation of DCN underexpression with the presence of KRAS
mutations, suggests that DCN expression is affected by the
presence of activating KRAS mutations, lowering the
amount of the important tumour suppressor protein
decorin.
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